Loncom Pharma's Atomoxetine HCl APIs are central to the development of advanced medications for Attention Deficit Hyperactivity Disorder (ADHD), providing a non-stimulant, selective norepinephrine reuptake inhibitor that is essential in the modulation of attention and behavior. These APIs are crafted to meet the highest standards, ensuring efficacy and safety for patients seeking alternatives to traditional stimulant therapies.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
